Top

Strahlentherapie und Onkologie

Published in:

01-12-2018 | Original Article

Unilateral cochlea sparing in locoregionally advanced head and neck cancer: a planning study

Authors: L. H. Braun, K. Braun, B. Frey, S. M. Wolpert, H. Löwenheim, D. Zips, S. Welz

Published in: Strahlentherapie und Onkologie | Issue 12/2018

Abstract

Background

Cochlea sparing can reduce late ototoxicity in head and neck cancer patients treated with cisplatin-based radiochemotherapy. In this situation, a mean cochlear dose (MCD) constraint of 10 Gy has been suggested by others based on the dose–effect relationship of clinical data. We aimed to investigate whether this is feasible for primary and postoperative radiochemotherapy in locoregionally advanced tumors without compromising target coverage.

Patients and methods

Ten patients treated with definitive and ten patients treated with adjuvant intensity-modulated radiotherapy (IMRT) and concurrent chemotherapy were investigated. The cochleae and a planning risk volume (PRV) with a 3 mm margin were newly delineated, whereas target volumes and other organs at risk were not changed. The initial plan was recalculated with a constraint of 10 Gy (MCD) on the low-risk side. The quality of the resulting plan was evaluated using the difference in the equivalent uniform dose (EUD).

Results

A unilateral MCD of below 10 Gy could be achieved in every patient. The mean MCD was 6.8 Gy in the adjuvant cohort and 7.6 Gy in the definitive cohort, while the non-spared side showed a mean MCD of 18.7 and 30.3 Gy, respectively. The mean PRV doses were 7.8 and 8.4 Gy for the spared side and 18.5 and 29.8 Gy for the non-spared side, respectively. The mean EUD values of the initial and recalculated plans were identical. Target volume was not compromised.

Conclusion

Unilateral cochlea sparing with an MCD of less than 10 Gy is feasible without compromising the target volume or dose coverage in locoregionally advanced head and neck cancer patients treated with IMRT. A prospective evaluation of the clinical benefit of this approach as well as further investigation of the dose–response relationship for future treatment modification appears promising.

Adunka OF, Buchman CA (2007) Cochlear implantation in the irradiated temporal bone. J Laryngol Otol 121(01):83–86. https://doi.org/10.1017/S0022215106002180 CrossRefPubMed

Bhandare N, Antonelli P, Morris C, Malayapa R, Mendenhall W (2007) Ototoxicity after radiotherapy for head and neck tumors. Int J Radiat Oncol Biol Phys 67(2):469–479. https://doi.org/10.1016/J.IJROBP.2006.09.017 CrossRefPubMed

Bhandare N, Jackson A, Eisbruch A, Pan CC, Flickinger JC, Antonelli P, Mendenhall WM (2010) Radiation therapy and hearing loss. Int J Radiat Oncol Biol Phys 76(3 Suppl). https://doi.org/10.1016/j.ijrobp.2009.04.096 CrossRefPubMedPubMedCentral

Bhandare N, Mendenhall WM, Antonelli PJ (2009a) Radiation effects on the auditory and vestibular systems. Otolaryngol Clin North Am. https://doi.org/10.1016/j.otc.2009.04.002 CrossRefPubMed

Bhandare N, Mendenhall WM, Antonelli PJ (2009b) Radiation effects on the auditory and vestibular systems. Otolaryngol Clin North Am. https://doi.org/10.1016/j.otc.2009.04.002 CrossRefPubMed

Blanchard P, Baujat P, Holostenco V, Bourredjem A, Baey C, Bourhis J, Pignon J (2011) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): A comprehensive analysis by tumour site. Radiother Oncol 100(1):33–40. https://doi.org/10.1016/J.RADONC.2011.05.036 CrossRefPubMed

Brouwer CL, Steenbakkers RJHM, Bourhis J, Budach W, Grau C, Grégoire V et al (2015) CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines. Radiother Oncol 117:83–90. https://doi.org/10.1016/j.radonc.2015.07.041 CrossRefPubMed

Cohen SM, Turley R (2009) Coprevalence and impact of dysphonia and hearing loss in the elderly. Laryngoscope 119(9):1870–1873. https://doi.org/10.1002/lary.20590 CrossRefPubMed

Das IJ, Andersen A, Chen ZJ, Dimofte A, Glatstein E, Hoisak J et al (2017) State of dose prescription and compliance to international standard (ICRU-83) in intensity modulated radiation therapy among academic institutions. Pract Radiat Oncol 7(2):e145–e155. https://doi.org/10.1016/J.PRRO.2016.11.003 CrossRefPubMed

10.

Eisbruch A (2009) Radiotherapy: IMRT reduces xerostomia and potentially improves QoL. Nat Rev Clin Oncol 6(10):567–568. https://doi.org/10.1038/nrclinonc.2009.143 CrossRefPubMed

11.

Fiorino C, Dell’Oca I, Pierelli A, Broggi S, Cattaneo GM, Chiara A et al (2007) Simultaneous Integrated Boost (SIB) for nasopharynx cancer with helical tomotherapy. Strahlenther Onkol 183(9):497–505. https://doi.org/10.1007/s00066-007-1698-x CrossRefPubMed

12.

Gabriele P, Orecchia R, Magnano M, Albera R, Sannazzari G (1992) Vestibular apparatus disorders after external radiation therapy for head and neck cancers. Radiother Oncol 25(1):25–30. https://doi.org/10.1016/0167-8140(92)90191-V CrossRefPubMed

13.

Genovesi D, Perrotti F, Trignani M, Di Pilla A, Vinciguerra A, Augurio A et al (2015) Delineating brachial plexus, cochlea, pharyngeal constrictor muscles and optic chiasm in head and neck radiotherapy: a CT-based model atlas. Radiol Med 120:352–360. https://doi.org/10.1007/s11547-014-0448-2 CrossRefPubMed

14.

Hawkins P, Lee J, Mao Y, Li P, Green M, Worden F et al (2017) Sparing all salivary glands with IMRT for head and neck cancer: Longitudinal study of patient-reported xerostomia and head-and-neck quality of life. Radiother Oncol. https://doi.org/10.1016/J.RADONC.2017.08.002 CrossRefPubMedPubMedCentral

15.

Hitchcock YJ, Tward JD, Szabo A, Bentz BG, Shrieve DC (2009) Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys 73(3):779–788. https://doi.org/10.1016/j.ijrobp.2008.05.040 CrossRefPubMed

16.

Huang E, Teh BS, Strother DR, Davis QG, Chiu JK, Lu HH, Carpenter LS, Mai WY, Chintagumpala MM, South M, Grant WH 3rd, Butler EB, Woo SY (2002) Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys 52(3):599-605CrossRef

17.

Jereczek-Fossa BA, Zarowski A, Milani F, Orecchia R (2003) Radiotherapy-induced ear toxicity. Cancer Treat Rev. https://doi.org/10.1016/S0305-7372(03)00066-5 CrossRefPubMed

18.

Johannesen TB, Rasmussen K, Winther FØ, Halvorsen U, Lote K (2002) Late radiation effects on hearing, vestibular function, and taste in brain tumor patients. Int J Radiat Oncol Biol Phys 53:86–90CrossRef

19.

Karasawa T, Steyger PS (2016) An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol Lett 237(3):219–227. https://doi.org/10.1016/j.toxlet.2015.06.012.An CrossRef

20.

Landier W (2016) Ototoxicity and cancer therapy. Cancer. https://doi.org/10.1002/cncr.29779 CrossRefPubMed

21.

Low W‑K, Gopal K, Goh LK, Fong KW (2006) Cochlear implantation in postirradiated ears: outcomes and challenges. Laryngoscope 116(7):1258–1262. https://doi.org/10.1097/01.mlg.0000225935.80559.11 CrossRefPubMed

22.

Low W‑K, Tan MG, Chua AW, Sun L, Wang D‑Y (2009) 12th Yahya cohen memorial lecture—the cellular and molecular basis of radiation-induced sensori-neural hearing loss. Ann Acad Med Singapore 38(1):91–94PubMed

23.

Low WK, Burgess R, Fong KW, Wang DY (2005) Effect of radiotherapy on retro-cochlear auditory pathways. Laryngoscope 115(10):1823–1826. https://doi.org/10.1097/01.mlg.0000175061.59315.58 CrossRefPubMed

24.

Monzani D, Galeazzi GM, Genovese E, Marrara A, Martini A (2008) Psychological profile and social behaviour of working adults with mild or moderate hearing loss. Acta Otorhinolaryngol Italica 28(2):61–66 (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/18669069)

25.

Mujica-Mota M, Waissbluth S, Daniel SJ (2014) Characteristics of radiation-induced sensorineural hearing loss in head and neck cancer: a systematic review. Head Neck 36(10):1391. https://doi.org/10.1002/HED CrossRef

26.

Nguyen NP, Ceizyk M, Vinh-Hung V, Sroka T, Jang S, Khan R et al (2012) Feasibility of tomotherapy to reduce cochlea radiation dose in patients with locally advanced nasopharyngeal cancer. Tumori J 98(6):709–714. https://doi.org/10.1700/1217.13493 CrossRef

27.

Nguyen N, Smith-Raymond L, Vinh-Hun V, Sloan D, Davis R, Vosc P et al (2011) Feasibility of tomotherapy to spare the cochlea from excessive radiation in head and neck cancer. Oral Oncol 47(5):414–419. https://doi.org/10.1016/J.ORALONCOLOGY.2011.03.011 CrossRefPubMed

28.

Pacholke HD, Amdur RJ, Schmalfuss IM, Louis D, Mendenhall WM (2005) Contouring the middle and inner ear on radiotherapy planning scans. Am J Clin Oncol 28:143–147. https://doi.org/10.1097/01.coc.0000143847.57027.16 CrossRefPubMed

29.

Pan CC, Eisbruch A, Lee JS, Snorrason RM, Ten Haken RK, Kileny PR (2005) Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys. https://doi.org/10.1016/j.ijrobp.2004.08.019 CrossRefPubMed

30.

Peng G, Wang T, Yang K, Zhang S, Zhang T, Li Q et al (2012) A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol 104(3):286–293. https://doi.org/10.1016/J.RADONC.2012.08.013 CrossRefPubMed

31.

Pignon J‑P, le Maître A, Maillard E, Bourhis J (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 92(1):4–14. https://doi.org/10.1016/J.RADONC.2009.04.014 CrossRefPubMed

32.

Scobioala S, Parfitt R, Ebrahimi F, Matulat P, Zehnhoff-Dinnesen A, Eich H (2017) Impact of radiation technique, fraction dose and total cisplatin dose on hearing: Retrospective analysis of 29 medulloblastoma patients. Strahlenther Onkol 193(1):96–S97. https://doi.org/10.1007/s00066-017-1137-6 CrossRef

33.

Scoccianti S, Detti B, Gadda D, Greto D, Furfaro I, Meacci F et al (2015) Organs at risk in the brain and their dose-constraints in adults and in children: A radiation oncologist’s guide for delineation in everyday practice. Radiother Oncol 114:230–238. https://doi.org/10.1016/j.radonc.2015.01.016 CrossRefPubMed

34.

Strojan P, Hutcheson KA, Eisbruch A, Beitler JJ, Langendijk JA, Lee AWM et al (2017) Complications of treatment treatment of late sequelae after radiotherapy for head and neck cancer. Cancer Treat Rev 59:79–92. https://doi.org/10.1016/j.ctrv.2017.07.003 CrossRefPubMedPubMedCentral

35.

Sun Y, Yu XL, Luo W, Lee AWM, Wee JTS, Lee N et al (2014) Recommendation for a contouring method and atlas of organs at risk in nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy. Radiother Oncol 110:390–397. https://doi.org/10.1016/j.radonc.2013.10.035 CrossRefPubMed

36.

Theunissen EAR, Bosma SCJ, Zuur CL, Spijker R, van der Baan S, Dreschler WA et al (2014) Sensorineural hearing loss in patients with head and neck cancer after chemoradiotherapy and radiotherapy: A systematic review of the literature. Head Neck 36(10):1391. https://doi.org/10.1002/HED CrossRef

37.

Theunissen EAR, Dreschler WA, Latenstein MN, Rasch CRN, van der Baan S, de Boer JP et al (2014) A new grading system for ototoxicity in adults. Ann Otol Rhinol Laryngol 123(10):711–718. https://doi.org/10.1177/0003489414534010 CrossRefPubMed

38.

Theunissen E, Zuur CL, Lopez Yurda M, Van Der BS, Kornman AF, De Boer PJ et al (2014) Cochlea sparing effects of intensity modulated radiation therapy in head and neck cancers patients: a long-term follow-up study. J Otolaryngol Head Neck Surg 43. https://doi.org/10.1186/s40463-014-0030-x CrossRefPubMedPubMedCentral

39.

Van Der Laan HP, Bijl HP, Steenbakkers RJHM, Van Der Schaaf A, Chouvalova O, Vemer-Van Den Hoek JGM et al (2015) Prediction of dysphagia acute symptoms during the course of head and neck radiotherapy or chemoradiation are strong predictors of late dysphagia. Radiother Oncol 115:56–62. https://doi.org/10.1016/j.radonc.2015.01.019 CrossRef

40.

Vergeer MR, Doornaert PAH, Rietveld DHF, Leemans CR, Slotman BJ, Langendijk JA (2009) Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program. Int J Radiat Oncol Biol Phys 74(1):1–8. https://doi.org/10.1016/j.ijrobp.2008.07.059 CrossRefPubMed

41.

Wu Y, Hu W‑H, Xia Y‑F, Ma J, Liu M‑Z, Cui N‑J (2007) Quality of life of nasopharyngeal carcinoma survivors in Mainland China. Qual Life Res 16(1):65–74. https://doi.org/10.1007/s11136-006-9113-0 CrossRefPubMed

42.

Zuur CL, Simis YJ, Lamers EA, Hart AA, Dreschler WA, Balm AJ, Rasch CR (2009) Risk factors for hearing loss in patients treated with intensity-modulated radiotherapy for head-and-neck tumors. Int J Radiat Oncol Biol Phys 74(2):490–496. https://doi.org/10.1016/j.ijrobp.2008.08.011 CrossRefPubMed

43.

Theunissen EA, Zuur CL, Jozwiak K, Lopez-Yurda M, Hauptmann M, Rasch CR, van der Baan S, de Boer JP, Dreschler WA, Balm AJ (2015) Prediction of hearing loss due to cisplatin chemoradiotherapy. JAMA Otolaryngol Head Neck Surg 141(9):810–815CrossRef

44.

Lange J (2013) Klinische Anatomie des Ohres. Springer, Wien

Title: Unilateral cochlea sparing in locoregionally advanced head and neck cancer: a planning study
Authors: L. H. Braun
K. Braun
B. Frey
S. M. Wolpert
H. Löwenheim
D. Zips
S. Welz
Publication date: 01-12-2018
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 12/2018
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-018-1344-9

At a glance: The STEP trials

Springer Medicine

Unilateral cochlea sparing in locoregionally advanced head and neck cancer: a planning study

Abstract

Background

Patients and methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2018

Postoperative local fractionated radiotherapy for resected single brain metastases

Health services research in German radiation oncology: new opportunities to advance cancer care

Radiosurgery of vestibular schwannoma: prognostic factors for hearing outcome using 3D-constructive interference in steady state (3D-CISS)

Pattern of dysphagia after swallowing-sparing intensity-modulated radiotherapy (IMRT) of head and neck cancers: results of a mono-institutional prospective study

Correction to: Prof. Dr. Luther W. Brady verstorben

The impact of MRI steady-state sequences as an additional assessment modality in vestibular schwannoma patients after LINAC stereotactic radiotherapy or radiosurgery